A Double-Blind, Randomized, Placebo-Controlled, Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of THN391 in Early Alzheimer’s Disease Subjects

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519899-72-00

Acronym

THN391-NEU-102

Enrollment

Registered

2025-04-14

Start date

2025-05-08

Completion date

Unknown

Last updated

2025-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

None listed

Sex/Gender

All

Age

65 Years to No maximum

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026